Shattuck Labs names Shoba Ravichandran senior vice president, clinical development
Bitget2026/10/01 11:00- Shattuck Labs named Shoba Ravichandran as senior vice president, clinical development to lead the SL-325 hidradenitis suppurativa program.
- Ravichandran previously spent more than a decade at Novartis, most recently as senior global program clinical head.
- She led the global approval of Cosentyx in hidradenitis suppurativa, also led Phase 3 start-up for remibrutinib in the disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jefferies lowers SEA target price to $142
Zenix Robotics Invests 5.08 Billion Won to Expand Production Capacity
Anthropic (ANT.US) targets IPO at trillion-dollar valuation; venture capitalists warn it may signal the peak of the AI market
Venture capitalist Selby warns that Anthropic’s trillion-dollar valuation IPO could signal the peak of the AI market, and the expiration of the lock-up period may trigger a chain reaction of corrections.
Wall Street's "Great Rotation" Underway: AI Trading Fades, Tech Stocks Out of Favor, Capital Flows Shift to Defensive Sectors
Analysts point out that as investors shift their bets from high-risk technology sectors to defensive stocks, the market is currently in a "state of alert".
Crypto prices
More
